July 17, 2013
Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral selective BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors.
Abstract with same title was presented at ASCO 2013. This time, they could show more mature data.
They have ARRY-520 for multiple myeloma and ARRY-614 for myelodysplastic syndrome, two drugs that Array is going to develop on its own, at least in US. They also have ARRY-797 for pain and ARRY-502 for asthma. All rights to these two drugs belong to ARRY and they want to partner them.